<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034550</url>
  </required_header>
  <id_info>
    <org_study_id>C17-47</org_study_id>
    <nct_id>NCT04034550</nct_id>
  </id_info>
  <brief_title>Cohort of Hospitalized Patients Suspected of Leptospirosis</brief_title>
  <acronym>COLEPT</acronym>
  <official_title>Cohort of Hospitalized Patients Suspected of Leptospirosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COLEPT is a prospective interventional study that intends to better inform about
      leptospirosis, a neglected zoonotic infectious disease. During prospective follow-up of
      hospitalized acute leptospirosis cases, the participants will be assessed during 1 year for
      epidemiological, clinical, bacteriological and immunological data. Main intervention consists
      in blood sampling and biological bank constitution.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease severity</measure>
    <time_frame>0 to 21 days after onset of symptoms</time_frame>
    <description>Rate of death or severe organ insuffisiency</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Leptospirosis</condition>
  <arm_group>
    <arm_group_label>hospitalized patients diagnosed with leptospirosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hospitalized patients diagnosed with leptospirosis: 12 months of follow up with biological samples and data collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood and urine sampling and blood banking</intervention_name>
    <description>In routine management, blood and urine will be sampled for each patients and specific analyses carried out. Only blood samples will be banked.</description>
    <arm_group_label>hospitalized patients diagnosed with leptospirosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinico-biological manifestations compatible with acute leptospirosis OR proven
             leptospirosis with serological testing or PCR

          -  onset of symptoms within 21 days

          -  participant benefits of health insurance

        Exclusion Criteria:

          -  participant's refusal, or refusal from his relatives in case of major incapacity of
             the eligible participant precluding expression of his will (coma, stay in intensive
             care unit))
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loïc RAFFRAY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Reunion, INSERM, CNRS, IRD UMR PIMIT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier MAILLARD, PharmD, MPH</last_name>
    <phone>+262262359492</phone>
    <email>olivier.maillard@chu-reunion.fr</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leptospirosis</keyword>
  <keyword>hospitalization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leptospirosis</mesh_term>
    <mesh_term>Weil Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

